What are the highlights of the European Hematology Association 2022 ?

The highlight of the European Hematology Association 2022 was the presentation of the results of a trial called QUANTUM-First, which evaluated the combination of quizartinib with chemotherapy in newly diagnosed FLT3-ITD+ AML patients. The trial showed that compared to standard chemotherapy alone, the combination of quizartinib with chemotherapy significantly improved overall survival (OS) in these patients. The median OS was doubled to 31.9 months, and the risk of death was reduced by 22.4%. This trial was an international, randomized, double-blind, placebo-controlled study that enrolled newly diagnosed FLT3-ITD+ AML patients aged 18-75 years with a FLT3-ITD allelic frequency of at least 3%. Participants were randomly assigned to receive quizartinib 40mg (days 8-21) or placebo combined with standard chemotherapy (days 1-7: cytarabine) and either doxorubicin or idarubicin (days 1-3), as up to 2 cycles of induction therapy. They then received consolidation therapy with high-dose cytarabine plus quizartinib or placebo, and/or transplantation, followed by maintenance therapy with quizartinib or placebo alone for up to 36 cycles. The results of this trial are a major breakthrough for newly diagnosed FLT3-ITD+ AML patients and provide new insights for future treatment strategies.